Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?
Dalgisio LecisFrancesca Romana PrandiLucy BaroneMartina BelliDomenico SergiSusanna LongoSaverio MuscoliFrancesco RomeoMassimo FedericiStamatios LerakisFrancesco BarillàPublished in: Biomolecules (2023)
Atherosclerosis is a chronic inflammatory disease characterized by lipid and inflammatory cell deposits in the inner layer of large- and medium-sized elastic and muscular arteries. Diabetes mellitus (DM) significantly increases the risk of cardiovascular diseases and the overall and cardiovascular mortality, and it is a pro-atherogenic factor that induces atherosclerosis development and/or accelerates its progression through a multifactorial process. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new class of drugs, belonging to the armamentarium to fight type 2 DM, that have shown robust reductions in atherosclerotic events and all-cause mortality in all studies. Preclinical studies have shown that GLP-1RAs play a role in the immunomodulation of atherosclerosis, affecting multiple pathways involved in plaque development and progression. In this review, we wanted to explore the translational power of such preclinical studies by analyzing the most recent clinical trials investigating the atheroprotective effect of GLP-1RAs.
Keyphrases
- cardiovascular disease
- clinical trial
- cell therapy
- case control
- wild type
- cardiovascular events
- coronary artery disease
- oxidative stress
- single cell
- type diabetes
- glycemic control
- randomized controlled trial
- stem cells
- anti inflammatory
- blood flow
- mesenchymal stem cells
- bone marrow
- study protocol
- preterm infants
- drug induced
- placebo controlled